Our results demonstrated that HIF-1α increased sharply in HCC cells treated with lenvatinib, binding to HRE of STOML2 promoter, and thus transcriptionally promoted the expression of STOML2. The gene discussed is STOML2; the disease is hepatocellular carcinoma.